How should pharma approach patient collaboration in the 2020s?

From the growing range of patient entities through to new possibilities stemming from technology and patient-generated data, pharma has more and more ways to innovate when it comes to collaborating with patients. 
  Now pharma needs to identify the ones that will really move the dial. “Clearly there is a shift from patient engagement as a nice-to-have, feel-good activity, to something which is more strategic,” says Vanessa Pott, Director, Patient Advocacy& Strategic Partnerships at Merck. “It’s really important for us to stay abreast of all the external trends.”  To stay ahead of the curve in the coming years, pharma will need to address these trends. “This includes everything from appreciating the nuances of the vast diversity within patient communities, through to developing consistent and compliant approaches to collaboration,” says Dr. Amy Nicole Nayar, Head of Global Patient Relations at AbbVie. “The companies that learn how to harness this opportunity quickly, and the patients they serve, will benefit most.” Building strategic partnerships over transactional relationships The nature of these partnerships is already changing, says Pott. “Our main goal is to strategically engage with patients and make sure that the insights we get actually shape our decision-making, so that we’re not just being patient-centric for patient-centricity’s sake. It’s moving from transactional relationships to long-term strategic partnerships.” 

Mer...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news